Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

NRBO NeuroBo Pharmaceuticals

Watchlist
1.430
-0.020-1.38%
Close 12/01 16:00 ET
1.440
+0.010+0.70%
Pre Mkt Price 12/02 05:06 ET
High
1.480
Open
1.460
Turnover
1.21M
Low
1.370
Pre Close
1.450
Volume
853.90K
Market Cap
9.30M
P/E(TTM)
Loss
52wk High
63.850
Shares
6.50M
P/E(Static)
Loss
52wk Low
1.130
Float Cap
9.05M
Bid/Ask %
93.33%
Historical High
16192.494
Shs Float
6.33M
Volume Ratio
0.07
Historical Low
1.130
Dividend TTM
--
Div Yield TTM
--
P/B
1.57
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
13.49%
Amplitude
7.58%
Avg Price
1.418
Lot Size
1
Float Cap
9.05M
Bid/Ask %
93.33%
Historical High
16192.494
Shs Float
6.33M
Volume Ratio
0.07
Historical Low
1.130
Dividend TTM
--
P/B
1.57
Dividend LFY
--
Turnover Ratio
13.49%
Amplitude
7.58%
Avg Price
1.418
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Listing Date: 08/05/2016
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist